Recruiting NA INTERVENTIONAL 1-arm
NCT06649474
Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1 (HEPATOXALI)
Sponsor: University Hospital, Clermont-Ferrand
Conditions
Adenocarcinoma Oesophagogastric Cancer Pancreatic Cancer Resectable Esophageal Cancer Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Resectable Pancreatic Adenocarcinoma
Interventions
assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy
Updated 1 time since 2024 Last updated: Oct 17, 2024 Started: Sep 6, 2024 Primary completion: Jun 30, 2028 Completion: Jun 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A NA clinical study on Adenocarcinoma and Oesophagogastric Cancer, this trial is actively recruiting participants. The trial is conducted by University Hospital, Clermont-Ferrand and has accumulated 1 data snapshot since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Recruiting — NA
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- University Hospital, Clermont-Ferrand
Data source: University Hospital, Clermont-Ferrand
For direct contact, visit the study record on ClinicalTrials.gov .